Cell-free protein synthesis (CFPS) enables protein production from a DNA or mRNA template in 2–6 hours, without living cells. The open reaction environment allows direct manipulation of transcription, translation, and folding conditions — making CFPS the fastest route from gene to protein for screening, toxic protein production, and incorporation of unnatural amino acids. This guide covers platform selection, reaction setup, yield optimization, and the practical decision of when cell-free expression outperforms traditional in vivo systems.
What Is Cell-Free Protein Synthesis?
Cell-free protein synthesis uses the transcription and translation machinery extracted from cells — ribosomes, tRNAs, aminoacyl-tRNA synthetases, initiation factors, and energy regeneration enzymes — to produce protein in a test tube. The technology was pioneered by Nirenberg and Matthaei in 1961 to decode the genetic code, and has since evolved into a robust platform for both research and manufacturing.
A CFPS reaction requires four core components:
- Cell extract or purified components — provides the translation machinery
- DNA or mRNA template — encodes the target protein under a strong promoter (typically T7)
- Energy regeneration system — ATP, GTP, and a secondary energy source (creatine phosphate, 3-phosphoglycerate, or phosphoenolpyruvate)
- Amino acids and cofactors — all 20 amino acids, Mg²+, K+, and NTPs
Unlike in vivo expression, CFPS has no cell membrane barrier. This means you can directly add or remove components — supplementing chaperones for difficult proteins, adding labelled amino acids for NMR studies, or spiking in unnatural amino acids for click chemistry.
When to Use CFPS vs In Vivo Expression
CFPS is not a universal replacement for cell-based expression — it excels in specific scenarios where speed, access to the reaction environment, or protein toxicity make in vivo production impractical. The decision depends on your protein, your timeline, and the scale you need.
Choose CFPS when:
- Speed is critical — CFPS skips cloning, transformation, colony selection, and overnight cultures. You go from linear PCR product to protein in the same day.
- The protein is toxic to host cells — membrane-disrupting peptides, restriction enzymes, and cytotoxic proteins that kill the host can be produced freely without viability constraints.
- You need unnatural amino acids — the open reaction allows direct addition of orthogonal tRNA/aminoacyl-tRNA synthetase pairs and non-canonical amino acids for click chemistry, PEGylation sites, or spectroscopic labels.
- High-throughput screening — CFPS reactions scale down to 1–5 µL in 384-well plates, enabling screening of hundreds of constructs in a single afternoon.
- Membrane proteins — co-translational insertion into nanodiscs, liposomes, or detergent micelles bypasses the toxicity and misfolding problems of in vivo membrane protein overexpression.
Stick with in vivo expression when:
- You need milligram-to-gram quantities — a 1 L E. coli fermentation yields 0.1–5 g of protein at a fraction of the per-milligram cost of CFPS.
- Complex mammalian glycosylation is required — CHO and HEK293 cells provide the full Golgi processing pathway that no cell-free system fully replicates.
- The protein requires multi-subunit assembly in vivo — some complexes assemble co-translationally on polyribosomes and are difficult to reconstitute from separately synthesized subunits.
Comparing CFPS Platforms
Six major CFPS platforms are in routine use, each with distinct trade-offs between yield, cost, post-translational modification (PTM) capability, and preparation complexity. E. coli extract dominates for prokaryotic proteins, while wheat germ extract leads among eukaryotic systems for raw yield.
| Platform | Batch Yield (µg/mL) | Dialysis Yield (µg/mL) | Cost/µL (in-house) | PTM Capability | Extract Prep Time |
|---|---|---|---|---|---|
| E. coli extract | 1,000–2,300 | 3,000–4,000 | $0.019 | None (disulfide bonds with iodoacetamide pre-treatment) | 1–2 days |
| Wheat germ extract | 1,600 | up to 20,000 | $0.05–0.10 | Disulfide bonds (with GSSG) | 4–5 days |
| PURE system | 100–400 | 500–800 | $0.30–0.50 | None (defined composition) | N/A (commercial) |
| Rabbit reticulocyte | 10–100 | 200–500 | $0.20–0.40 | Signal peptide processing, some glycosylation | ~8 days |
| Insect cell (Sf21) | 50–285 | 400–600 | $0.10–0.20 | Core glycosylation, disulfide bonds | 2–3 days |
| CHO / HeLa extract | 50–300 | 500–980 | $0.15–0.30 | Glycosylation, disulfide bonds, lipid modification | 2–3 days |
The PURE system (Protein synthesis Using Recombinant Elements) deserves special mention. Developed by Shimizu et al., it replaces crude extract with individually purified translation components. The trade-off is clear: 5–10× lower yield and 15–25× higher cost, but near-zero nuclease and protease activity. This makes PURE ideal for producing proteins sensitive to degradation and for mechanistic studies where you need to know exactly what is in the reaction.
Setting Up a CFPS Reaction
A standard E. coli extract CFPS reaction contains 33% (v/v) cell extract, 25–40% master mix (amino acids, NTPs, energy source, salts), and the remainder as template DNA and water. The most common protocol uses a T7 promoter-driven plasmid with the PANOx-SP energy regeneration system (3-phosphoglyceric acid as secondary energy source).
Successful CFPS depends on getting three things right:
- Extract quality — harvest cells at mid-log phase (OD600 2.0–4.0 for BL21 Star DE3), lyse gently (homogenizer at 14,000–20,000 psi, single pass, or sonication), and run-off endogenous mRNA with a 60–80 min incubation at 37°C.
- Mg²+ optimization — titrate MgGlu2 from 4–20 mM in 2 mM steps for each new batch of extract. Optimal concentration varies batch-to-batch.
- Template concentration — typically 5–20 nM plasmid or 1–10 nM linear PCR product. Higher concentrations do not increase yield and can inhibit translation through excess mRNA competition for ribosomes.
Worked Example: 50 µL E. coli CFPS Reaction
Target: Produce GFP as a positive control to validate a new extract batch.
Reaction composition:
| Component | Stock Concentration | Final Concentration | Volume (µL) |
|---|---|---|---|
| Cell extract | — | 33% v/v | 16.5 |
| Amino acid mix | 6 mM each | 2 mM each | 16.7 |
| ATP | 75 mM | 1.5 mM | 1.0 |
| GTP, CTP, UTP | 75 mM each | 0.9 mM each | 0.6 each (1.8 total) |
| 3-PGA | 1.4 M | 30 mM | 1.07 |
| MgGlu2 | 1 M | 10 mM* | 0.5 |
| KGlu | 3 M | 175 mM | 2.92 |
| T7 RNAP | 13 mg/mL | 0.1 mg/mL | 0.38 |
| Plasmid DNA (pJL1-GFP) | 500 nM | 10 nM | 1.0 |
| Nuclease-free water | — | — | to 50 µL |
*Optimize Mg²+ from 4–20 mM for each extract batch. 10 mM is a starting point.
Protocol:
- Thaw extract and master mix on ice. Keep all components cold until incubation.
- Prepare master mix (amino acids + NTPs + 3-PGA + salts + T7 RNAP) and aliquot.
- Add extract to master mix, then add DNA template last. Mix gently by pipetting — do not vortex.
- Incubate at 30°C for 4 hours (batch format). Protect from light if using fluorescent reporters.
- Measure GFP fluorescence (excitation 485 nm, emission 528 nm) directly in the reaction. For non-fluorescent proteins, run SDS-PAGE or Western blot.
Expected yield: 0.5–1.5 mg/mL GFP from a good extract batch.
Optimizing CFPS Yield
Optimization of CFPS yield can deliver up to 34-fold improvements over unoptimized conditions. The five most impactful variables, in order of typical effect size, are Mg²+ concentration, energy regeneration system, DNA template design, extract preparation method, and reaction temperature.
Mg²+ Concentration
Magnesium is required for ribosome assembly, tRNA charging, and NTP stability, but excess Mg²+ inhibits translation by stabilizing non-productive RNA structures. The optimal concentration varies by 4–8 mM between extract batches, making per-batch titration essential. Run a 6-point titration (4, 8, 10, 12, 16, 20 mM) with GFP as reporter before using a new extract for target proteins.
Energy Regeneration
The choice of secondary energy source affects both yield and reaction longevity. Three systems are in common use:
- Creatine phosphate / creatine kinase — the original system. Yields ~0.7 mg/mL. Simple but expensive due to the enzyme.
- Phosphoenolpyruvate (PEP) — yields ~0.5–1.0 mg/mL. Drops pH during the reaction due to pyruvate accumulation.
- 3-phosphoglyceric acid (3-PGA) — the current standard. Yields up to 2.3 mg/mL. Feeds into glycolysis endogenously without requiring additional enzymes, is inexpensive, and maintains stable pH.
Template Engineering
For maximum expression, use a strong T7 promoter with a consensus ribosome binding site (RBS) spaced 6–8 nucleotides upstream of the start codon. Linear expression templates (LETs) produced by PCR work well but may be degraded by exonucleases in crude extract — adding GamS protein (a RecBCD inhibitor from phage Lambda) at 1–3 µM stabilizes linear DNA and recovers yields to plasmid-equivalent levels.
Machine Learning Approaches
Recent work has applied active learning and Bayesian optimization to CFPS formulation, systematically exploring the combinatorial space of 10–15 reaction components. These approaches converge on near-optimal formulations in 3–4 iterative rounds of 50–100 reactions each, achieving up to 9-fold yield improvements over manual optimization. The key insight from these studies: component interactions (especially Mg²+ × K+ and amino acid ratios) dominate over individual concentrations.
E. coli Expression Optimizer
Deciding between cell-free and in vivo E. coli expression? Use our optimizer to evaluate strain, promoter, and induction conditions for in vivo alternatives.
Scale-Up and Industrial Applications
CFPS has been scaled from 10 µL screening reactions to 100 L production volumes. The transition from bench to manufacturing scale introduces oxygen transfer, mixing, and cost challenges that mirror those of conventional fermentation — though the timescales are shorter.
Reaction Formats
Three formats span the scale range:
- Batch (1 µL – 100 L) — simplest format. Reaction runs until energy substrates deplete (2–6 hours). Yields 1–2.3 mg/mL for E. coli extract.
- Continuous-exchange cell-free (CECF) — the reaction chamber is separated from a feeding reservoir by a dialysis membrane. Fresh substrates diffuse in, inhibitory byproducts diffuse out. Extends reaction to 12–24 hours and boosts yields 3–10× (up to 20 mg/mL for wheat germ).
- Continuous-flow — fresh reagents are pumped through the reaction vessel continuously. Enables steady-state production but requires more complex equipment.
Bioreactor-Scale CFPS
At volumes above 1 mL, dissolved oxygen becomes limiting. Actively aerating the reaction — via sparging, overlay, or thin-film reactors — increases yields dramatically. High dissolved oxygen conditions have pushed batch yields to 3.7 g/L in stirred-tank bioreactors, approaching the highest reported CFPS yields (4 g/L) at a cost of approximately $39 per gram of protein.
Industrial CFPS is already a reality for specific applications. Sutro Biopharma has produced antibody-drug conjugates (ADCs) containing site-specifically incorporated unnatural amino acids at clinical-grade scale. The open nature of the system allows consistent batch-to-batch quality that is difficult to achieve with living cells.
Cost at Scale
| Scale | Format | Estimated Cost/mg | Typical Application |
|---|---|---|---|
| 10–50 µL | Commercial kit (batch) | $50–200 | Construct screening, proof of concept |
| 50–500 µL | In-house extract (batch) | $10–30 | Protein characterization, assay development |
| 1–10 mL | In-house extract (CECF) | $3–15 | Structural biology, functional studies |
| 0.1–1 L | Bioreactor (batch) | $1–5 | Pre-clinical material |
| 1–100 L | Bioreactor (aerated batch) | $0.03–0.10 | Clinical manufacturing |
Emerging Applications
Beyond recombinant protein production, CFPS is enabling entirely new application categories that are difficult or impossible with cell-based systems.
Point-of-Care Diagnostics
Lyophilized CFPS reactions on paper strips can detect pathogen nucleic acids at room temperature. The toehold switch sensor architecture — a synthetic riboswitch that activates reporter gene translation only in the presence of a target RNA sequence — has been coupled with CFPS to detect Zika, Ebola, and SARS-CoV-2 RNA with sensitivity matching RT-qPCR. These paper-based diagnostics cost less than $1 per test, require no cold chain, and produce a visible colour change in 30–90 minutes.
Unnatural Amino Acid Incorporation
CFPS enables genetic code expansion by supplementing reactions with orthogonal aminoacyl-tRNA synthetase/tRNA pairs that read through amber stop codons (UAG). This allows site-specific incorporation of over 200 unnatural amino acids, including those bearing bioorthogonal handles (azides, alkynes, tetrazines) for subsequent conjugation with drugs, PEG chains, or fluorescent labels. The approach is central to next-generation ADC manufacturing.
On-Demand Biomanufacturing
Lyophilized CFPS kits that produce therapeutic proteins upon rehydration are being developed for field deployment in resource-limited settings. A single lyophilized pellet can produce a dose of antimicrobial peptide, vaccine antigen, or diagnostic reagent without refrigeration, sterile facilities, or trained personnel. This concept — sometimes called biomanufacturing at the point of need — could transform access to biologics in emergency response and remote healthcare scenarios.
Metabolic Engineering and Prototyping
CFPS serves as a rapid prototyping platform for metabolic pathways. By co-expressing 5–15 pathway enzymes simultaneously in a cell-free reaction, researchers can test pathway variants in hours rather than the weeks required for in vivo pathway construction. The TX-TL (transcription-translation) breadboard approach enables iterative design-build-test cycles for synthetic biology circuits before committing to cellular implementation.
Protein MW & Extinction Coefficient Calculator
Characterize your CFPS products. Calculate molecular weight from amino acid sequence and predict extinction coefficient for UV quantification.
Frequently Asked Questions
What is the typical protein yield from cell-free protein synthesis?
Yields vary widely by platform and format. E. coli extract-based CFPS produces 1.0–2.3 mg/mL in batch mode. Wheat germ systems achieve 1.6 mg/mL in batch and up to 20 mg/mL in continuous-exchange (dialysis) format. Reconstituted PURE systems yield 0.1–0.4 mg/mL but offer minimal nuclease and protease activity. Mammalian and insect cell extracts typically produce 0.05–0.3 mg/mL with native post-translational modifications.
When should I use cell-free protein synthesis instead of in vivo expression?
CFPS is preferred when you need results in hours instead of weeks (no cloning or cell culture required), when producing toxic proteins that would kill host cells, when incorporating unnatural amino acids, when screening many constructs in parallel (high-throughput), or when producing membrane proteins that misfold in vivo. For large-scale production above 1 gram, in vivo expression is usually more cost-effective.
How much does cell-free protein synthesis cost per reaction?
In-house E. coli extract preparation costs approximately $0.019 per microlitre of reaction, or roughly $21 per milligram of protein produced. Commercial kits cost $0.15–0.57 per microlitre, making them 8–30 times more expensive than in-house preparations. The cost difference becomes significant at scales above a few hundred microlitres.
What is the difference between cell extract and PURE system for CFPS?
Cell extract (lysate) systems contain the full cellular machinery including ribosomes, tRNAs, aminoacyl-tRNA synthetases, chaperones, and energy metabolism enzymes, yielding 1–2 mg/mL at low cost. PURE systems use individually purified components, yielding only 0.1–0.4 mg/mL but with minimal nuclease and protease activity, making them ideal for degradation-sensitive proteins and mechanistic studies.
Can cell-free protein synthesis produce proteins with post-translational modifications?
Yes, but with platform-dependent limitations. E. coli extracts cannot glycosylate proteins natively. Insect cell (Sf21) and CHO cell extracts contain endogenous microsomes that support core glycosylation, disulfide bond formation, and signal peptide processing. Wheat germ extracts support disulfide bonds when supplemented with oxidized glutathione. For complex mammalian-type glycosylation, CHO or HeLa extracts are the best cell-free option.
Related Tools
- E. coli Expression Optimizer — optimize strain, promoter, and induction conditions for in vivo E. coli expression when CFPS is not the best fit.
- Protein MW & Extinction Coefficient Calculator — calculate molecular weight and ε280 from sequence for quantifying CFPS products.
- Buffer Calculator — prepare CFPS reaction buffers with precise pH and ionic strength control.
References
- Gregorio NE, Levine MZ, Oza JP. A User’s Guide to Cell-Free Protein Synthesis. Methods and Protocols. 2019;2(1):24. doi:10.3390/mps2010024
- Batista AC, Soudier P, Kushwaha M, Faulon JL. Optimising protein synthesis in cell-free systems, a review. Engineering Biology. 2021;5(1):10–19. doi:10.1049/enb2.12004
- Zemella A, Thoring L, Hoffmeister C, Kubick S. Cell-Free Protein Synthesis: Pros and Cons of Prokaryotic and Eukaryotic Systems. ChemBioChem. 2015;16(17):2420–2431. doi:10.1002/cbic.201500340
- Chiba CH, Knirsch MC, Azzoni AR, Moreira AR, Stephano MA. Cell-Free Protein Synthesis: Advances on Production Process for Biopharmaceuticals and Immunobiological Products. BioTechniques. 2021;70(2):126–133. doi:10.2144/btn-2020-0155